In contrast, PTCL‐NOS had a much lower frequency of mutation in TET2 (24%) and DNMT3A (12%), and no mutation in RHOA, IDH2, and CD28. This evidence concerns the gene IDH2 and mature T-cell and NK-cell non-Hodgkin lymphoma.